Last edition
News about "Novartis Pharma AG"
GSK Completes Acquisition of Efimosfermin from Boston Pharmaceuticals for USD 2 Billion
GSK has completed its acquisition of efimosfermin alfa, a Phase III-ready investigational therapy for serious liver diseases, from Boston Pharmaceuticals in a deal worth up to USD 2 billion.
Novartis Pharma AG | 09/07/2025 | By Mrinmoy Dey | 126
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members